Search Results
Sep 02, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement
More news about: Edgewise Therapeutics
Aug 24, 2026, 08:00 ET Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for
More news about: Edgewise Therapeutics
Aug 06, 2026, 08:00 ET Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026
More news about: Edgewise Therapeutics
Jul 13, 2026, 09:30 ET Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
indépendant gouverné par une fondation, a annoncé aujourd'hui avoir finalisé l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics Inc. (Nasdaq : EWTX), pour un montant allant jusqu'à $2,65 milliards, comprenant un paiement initial de $1,55 milliard, ainsi que des paiements d'étapes réglementaires et
More news about: Servier
Jul 13, 2026, 08:30 ET Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments.
More news about: Servier
Jul 13, 2026, 08:30 ET Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments.
More news about: Servier
Jul 13, 2026, 08:30 ET Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously
More news about: Edgewise Therapeutics
Jul 01, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Jun 16, 2026, 07:00 ET Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
BOULDER, Colo., June 16, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500
More news about: Edgewise Therapeutics
Jun 03, 2026, 16:01 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Jun 01, 2026, 09:30 ET Servier projette d'acquérir l'activité dystrophie musculaire d'Edgewise Therapeutics
fondation, a annoncé aujourd'hui avoir conclu un accord pour l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics Inc. (Nasdaq : EWTX), une société biopharmaceutique spécialisée dans le développement de thérapies innovantes pour les troubles musculaires graves, pour un montant allant
More news about: Servier
Jun 01, 2026, 08:30 ET Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
foundation, today announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), a biopharmaceutical company focused on developing innovative therapies for serious muscle disorders, for up to $2.65 billion, including upfront payment
More news about: Servier
Jun 01, 2026, 08:30 ET Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
foundation, today announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), a biopharmaceutical company focused on developing innovative therapies for serious muscle disorders, for up to $2.65 billion, including upfront payment
More news about: Servier
Jun 01, 2026, 08:30 ET Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
BOULDER, Colo., June 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that it has entered into a definitive agreement under which Servier, an independent
More news about: Edgewise Therapeutics
May 12, 2026, 08:00 ET Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare
More news about: Edgewise Therapeutics
May 07, 2026, 08:00 ET Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
BOULDER, Colo., May 7, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.
More news about: Edgewise Therapeutics
May 04, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., May 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Apr 01, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Mar 10, 2026, 07:00 ET Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA
More news about: Edgewise Therapeutics
Mar 04, 2026, 08:00 ET Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
BOULDER, Colo., March 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the Leerink Global Healthcare Conference
More news about: Edgewise Therapeutics
Mar 03, 2026, 08:00 ET Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 2026 Muscular Dystrophy Association (MDA) Clinical and
More news about: Edgewise Therapeutics
Mar 02, 2026, 09:30 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics
Feb 26, 2026, 08:00 ET Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
BOULDER, Colo., Feb. 26, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2025 and recent business
More news about: Edgewise Therapeutics
Feb 05, 2026, 08:00 ET Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim
More news about: Edgewise Therapeutics
Feb 02, 2026, 08:00 ET Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced
More news about: Edgewise Therapeutics